Status:
COMPLETED
URO-BCG-4 : Bladder Tumors Immunotherapy
Lead Sponsor:
University Hospital, Rouen
Conditions:
Bladder Cancer
Eligibility:
All Genders
Brief Summary
Evaluation of maintenance BCG immunotherapy (dose 27 mg) in superficial bladder tumors. Two randomized arms (every 3 or 6 months) will be studied for a population of 300 patients.
Detailed Description
BCG maintenance immunotherapy 1/3 dose : 27 mg two randomized arms : 3 or 6 months for 36 months clinical side effects according to OMS score efficacy regarding recurrence : cytology and cystoscopy PS...
Eligibility Criteria
Inclusion
- Ta and T1 bladder tumors
Exclusion
- BCG contra-indications
Key Trial Info
Start Date :
June 1 2004
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
146 Patients enrolled
Trial Details
Trial ID
NCT00213655
Start Date
June 1 2004
End Date
December 1 2013
Last Update
July 31 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Charles Nicolle, University Hospital
Rouen, France, 76031